Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells

Sameena Khan, Deborah J. Burt, Christy Ralph, Fiona C. Thistlethwaite, Robert E. Hawkins, Eyad Elkord*

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

62 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells'. Together they form a unique fingerprint.

Immunology and Microbiology